The use of dipeptidyl peptidase-4 (DPP-4) inhibitors is not associated with an increased risk of hospitalization for community-acquired pneumonia, according to a study published in the April issue of Diabetes, Obesity and Metabolism.
Researchers utilized data from the UK Clinical Practice Research Datalink and the Hospital Episodes Statistics database to identify new users of antidiabetic drugs between 2007 and 2012. Comparisons were made between cases hospitalized for incident community-acquired pneumonia and up to 20 controls who were matched for age, duration of treated diabetes, calendar year, and duration of follow-up.
- Disorders & Diseases
- Public Health
- Products & Treatment
- Department Management